CD19 and neoplasm: Interestingly, patients, who relapsed with antigen‐positive tumor cells after treatment with anti‐CD19 CAR T cells based on a murine scFv, could be successfully treated with CAR T cells based on either a humanized anti‐CD19 scFv [79] or a 'fully human' anti‐CD22 scFv.